Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus

Publisher:
Nature Publishing Group
Publication Type:
Journal Article
Citation:
Gene Therapy, 2004, 11 (21), pp. 1559 - 1567
Issue Date:
2004-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2010000583OK.pdf221.38 kB
Adobe PDF
Gene-directed enzyme prodrug therapy (GDEPT) based on the Escherichia coli enzyme, purine nucleoside phosphorylase (PNP), provides a novel strategy for treating slowly growing tumors like prostate cancer (CaP). PNP converts systemically administered prod
Please use this identifier to cite or link to this item: